Fibroblast-like cells as an effective feeder for the cultivation and derivation of new lines of human induced pluripotent stem cells

Novosadova, E.; Manuilova, E.; Arsenyeva, E.; Grivennikov, I.; Myasoedov, N.
September 2016
Doklady Biochemistry & Biophysics;Sep2016, Vol. 470 Issue 1, p353
Academic Journal
Induced pluripotent stem cells (iPSCs) can be a highly informative model of hereditary and sporadic human diseases. In the future, such cells can be used in substitution and regenerative therapy of a wide range of diseases and for the treatment of injuries and burns. The ability of iPSCs derived from patients with Parkinson's disease to differentiate into fibroblast-like cells (derivatives) was studied. It was found that these cells can serve as an effective feeder layer not only to maintain the pluripotency of allogenic and autologous iPSCs but also to derive new iPSC lines.


Related Articles

  • Stem-cell landmark.  // New Scientist;9/20/2014, Vol. 223 Issue 2987, p6 

    The article reports on the first human medical procedure to use induced pluripotent stem (iPS) cells, an operation on a 70-year old woman in Japan to treat age-related macular degeneration (AMD) in her eyes developed by Masayo Takahashi and colleagues at the RIKEN Center for Developmental Biology.

  • 1st Human Liver made from Stem Cells.  // IDA Times;Jan2014, Vol. 10 Issue 1, p16 

    The article reports that Japanese scientists Takanori Takebe and Hideki Taniguchi conducted a proof of concept study which showed the generation of artificial human liver from human-induced pluripotent stem cells (hiPSCs), along with information on three-dimensional organ culture.

  • Nanopatterned Human iPSC-Based Model of a Dystrophin-Null Cardiomyopathic Phenotype. Macadangdang, Jesse; Guan, Xuan; Smith, Alec; Lucero, Rachel; Czerniecki, Stefan; Childers, Martin; Mack, David; Kim, Deok-Ho // Cellular & Molecular Bioengineering;Sep2015, Vol. 8 Issue 3, p320 

    Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) offer unprecedented opportunities to study inherited heart conditions in vitro, but are phenotypically immature, limiting their ability to effectively model adult-onset diseases. Cardiomyopathy is becoming the leading cause...

  • Induced Pluripotent Stem Cells. Wilson, Kitchener D.; Wu, Joseph C. // JAMA: Journal of the American Medical Association;4/28/2015, Vol. 313 Issue 16, p1613 

    The article discusses the 2006 discovery of a method for creating induced pluripotent stem cells (iPSCs) by Takahashi and Shinya Yamanaka and colleagues, which won Yamanaka a Nobel Prize in 2012. Topics include the use of pluripotency to regenerate human organs and tissues, the time consumption...

  • Comparison of intraspinal and intrathecal implantation of induced pluripotent stem cell-derived neural precursors for the treatment of spinal cord injury in rats. Takashi Amemori; Ruzicka, Jiri; Romanyuk, Nataliya; Jhanwar-Uniyal, Meena; Sykova, Eva; Jendelova, Pavla // Stem Cell Research & Therapy;12/22/2015, Vol. 6, p1 

    Background: Stem cell treatment provides a promising therapy for patients with spinal cord injury (SCI). However, the applied stem cells exert their effects in different manners that are dependent on the route used for administration. Methods: In the present study, we administered neural...

  • Japan stem-cell trial stirs envy. Reardon, Sara; Cyranoski, David // Nature;9/18/2014, Vol. 513 Issue 7518, p287 

    The article discusses the clinical trials of induced pluripotent stem (iPS) cells. It states that the iPS cells are created by using a patient's own tissue and by inserting them in an adult's DNA cells to reprogram the cells to an embryonic-like state. The therapy was pioneered by Shinya...

  • Mesenchymal Stem Cells and Induced Pluripotent Stem Cells as Therapies for Multiple Sclerosis. Juan Xiao; Rongbing Yang; Biswas, Sangita; Xin Qin; Min Zhang; Wenbin Deng // International Journal of Molecular Sciences;2015, Vol. 16 Issue 5, p9283 

    Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory demyelinating disorder of the central nervous system that leads to permanent neurological deficits. Current MS treatment regimens are insufficient to treat the irreversible neurological disabilities. Tremendous progress in the...

  • Generation of clinical-grade human induced pluripotent stem cells in Xeno-free conditions. Juan Wang; Jie Hao; Donghui Bai; Qi Gu; Weifang Han; Lei Wang; Yuanqing Tan; Xia Li; Ke Xue; Pencheng Han; Zhengxin Liu; Yundan Jia; Jun Wu; Lei Liu; Liu Wang; Wei Li; Zhonghua Liu; Qi Zhou // Stem Cell Research & Therapy;11/12/2015, Vol. 6, p1 

    Introduction: Human induced pluripotent stem cells (hiPSCs) are considered as one of the most promising seed cell sources in regenerative medicine. Now hiPSC-based clinical trials are underway. To ensure clinical safety, cells used in clinical trials or therapies should be generated under GMP...

  • Regenerative Medicine: On the Vanguard of Health Care. Terzic, Andre; Folmes, Clifford D.; Martinez-Fernandez, Almudena; Behiar, Atta // Mayo Clinic Proceedings;Jul2011, Vol. 86 Issue 7, p600 

    An introduction is presented in which the editors discuss regenerative medicine which highlights the science and ethics of induced pluripotency.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics